Prosecution Insights
Prosecution Insights
Tech Center 3900 • Art Units: 1629 3991
This examiner grants 71% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18302666 | HIGH-EFFICIENCY STRENGTH PROGRAM USED FOR MAKING PAPER IN HIGH CHARGE DEMAND SYSTEM | Non-Final OA | ECOLAB USA INC. |
| 18794403 | Electrostatic Printing of Cyclodextrin Compositions | Non-Final OA | Verdant Technologies, LLC |
| 18790829 | CO-CRYSTAL FORMS OF A NOVOBIOCIN ANALOG AND PROLINE | Non-Final OA | Reata Pharmaceuticals, Inc. |
| 18766429 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PRESBYOPIA | Non-Final OA | Lenz Therapeutics Operations, Inc. |
| 18765066 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PRESBYOPIA | Non-Final OA | Lenz Therapeutics Operations, Inc. |
| 18765156 | CONTACT LENS COMPOSITIONS AND METHODS FOR THE TREATMENT OF PRESBYOPIA | Non-Final OA | Lenz Therapeutics Operations, Inc. |
| 18731215 | COMPOSITIONS AND METHODS FOR TREATING PSORIASIS | Non-Final OA | Sytheon Limited |
| 18412856 | PROCESSES FOR THE PRODUCTION OF FLUOROPROPANES AND HALOPROPENES | Final Rejection | THE CHEMOURS COMPANY FC, LLC |
| 18469808 | CRYSTALLINE N-[5-(AMINOSULFONYL)-4-METHYL-1,3-THIAZOL-2-YL]-N-METHYL-2-[4-(2-PYRIDINYL)PHENYL]ACETAMIDE MONO MESYLATE MONOHYDRATE HAVING A SPECIFIC PARTICLE SIZE DISTRIBUTION RANGE AND A SPECIFIC SURFACE AREA RANGE FOR USE IN PHARMACEUTICAL FORMULATIONS | Final Rejection | AiCuris Anti-Infective Cures GmbH |
| 18182228 | METHOD FOR THE PREPARATION OF (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1-6-NAPHTHYRIDINE-3-CARBOX-AMIDE AND THE PURIFICATION THEREOF FOR USE AS AN ACTIVE PHARMACEUTICAL INGREDIENT | Non-Final OA | Bayer Pharma Aktiengesellschaft |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy